Literature DB >> 7989479

Growth hormone secretion in recently operated acromegalic patients.

G van den Berg1, M Frölich, J D Veldhuis, F Roelfsema.   

Abstract

GH secretion patterns were studied in 14 recently transsphenoidally operated patients by measuring GH concentrations in blood sampled every 10 min over 24 h with a highly sensitive time-resolved immuno-fluorescent assay. Plasma GH concentrations were analyzed with a discrete peak detection program (Cluster) and a multiparameter deconvolution technique. Diurnal variations were analyzed by cosinor analysis. Nine or 10 days after pituitary surgery all patients had a normal plasma insulin-like growth factor-I level, and GH levels were suppressed to below 1.25 micrograms/L in 13 patients and to 1.3 micrograms/L in 1 subject during an oral glucose tolerance test. As we found a highly significant difference in GH secretion between male and female controls, the results obtained in patients were compared with those in their gender- and age-matched controls. Patients with active acromegaly displayed a significantly higher number of deconvolution-estimated secretory bursts (31/24 h in males and 27/24 h in female patients). The estimated secretion rate per 24 h was 25 times greater in female acromegalics and 100 times greater in male acromegalics than that in the controls. In patients with active acromegaly, about 50% of the GH was secreted in a nonpulsatile fashion. In contrast, normal subjects and patients shortly after pituitary surgery secreted GH predominantly (> 99%) in a pulsatile manner. By deconvolution analysis, the mean plasma half-life of GH was 19.7 min in treated male patients and 19.5 min in treated female patients (P = NS vs. controls) estimated mean total GH production/day, 188 micrograms in males and 240 micrograms in females (P = NS vs. controls); number of secretory bursts/24 h, 19.3 in males and 21.9 in females (P = NS vs. controls). In addition, we could not establish any difference in pulse characteristics with Cluster analysis between surgically treated patients and their control subjects. The present data suggest that the basic abnormality of acromegaly resides in the pituitary gland rather than in the hypothalamus.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7989479     DOI: 10.1210/jcem.79.6.7989479

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  15 in total

Review 1.  The evaluation and management of subclinical pituitary disease.

Authors:  S G Soule; H S Jacobs
Journal:  Postgrad Med J       Date:  1996-05       Impact factor: 2.401

Review 2.  Growth hormone pulsatility in acromegaly following radiotherapy.

Authors:  S R Peacey; S M Shalet
Journal:  Pituitary       Date:  1999-06       Impact factor: 4.107

3.  Long-term growth hormone treatment in short children with CKD does not accelerate decline of renal function: results from the KIGS registry and ESCAPE trial.

Authors:  Otto Mehls; Anders Lindberg; Dieter Haffner; Franz Schaefer; Elke Wühl
Journal:  Pediatr Nephrol       Date:  2015-07-22       Impact factor: 3.714

4.  Pituitary-hormone secretion by thyrotropinomas.

Authors:  Ferdinand Roelfsema; Simon Kok; Petra Kok; Alberto M Pereira; Nienke R Biermasz; Jan W Smit; Marijke Frolich; Daniel M Keenan; Johannes D Veldhuis; Johannes A Romijn
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

5.  Growth Hormone Dynamics in Healthy Adults Are Related to Age and Sex and Strongly Dependent on Body Mass Index.

Authors:  Ferdinand Roelfsema; Johannes D Veldhuis
Journal:  Neuroendocrinology       Date:  2015-07-28       Impact factor: 4.914

6.  Pituitary apoplexy in acromegaly, a long-term follow-up study in two patients.

Authors:  F Roelfsema; G van den Berg; H van Dulken; J D Veldhuis; S M Pincus
Journal:  J Endocrinol Invest       Date:  1998-05       Impact factor: 4.256

7.  The Pituitary in Gigantism.

Authors:  Bernd W. Scheithauer; Kalman T. Kovacs; Lucia Stefaneanu; Eva Horvath; Laurie A. Kane; William F. Young; Ricardo V. Lloyd; Raymond V. Randall; Dudley H. Davis
Journal:  Endocr Pathol       Date:  1995       Impact factor: 3.943

Review 8.  Human GH pulsatility: an ensemble property regulated by age and gender.

Authors:  J D Veldhuis; C Y Bowers
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

Review 9.  Nanomedicines in the treatment of acromegaly: focus on pegvisomant.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira; Johannes Romijn
Journal:  Int J Nanomedicine       Date:  2006

10.  Therapeutic options in the management of acromegaly: focus on lanreotide Autogel.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira; Johannes A Romijn
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.